News

Ellipses Pharma Develops Innovative Immuno-Oncology Therapy

Ellipses Pharma Develops Innovative Immuno-Oncology Therapy

Ellipses Pharma Unveils a Breakthrough in Immuno-Oncology

Ellipses Pharma Limited, a pioneering drug development company, is embarking on an exciting journey aimed at reshaping the landscape of cancer treatments. Their commitment lies in developing next-generation immuno-oncology therapies designed to meet the urgent needs of patients who have not responded to conventional treatments, especially checkpoint inhibitors.

In-Licensing of GENA-104

Recently, Ellipses Pharma announced its decision to in-license the global rights to GENA-104, an innovative immuno-oncology monoclonal antibody that specifically targets CNTN4. This protein has emerged as a crucial checkpoint protein, predominantly found in various tumor types, promising to offer new hope for cancer therapies.

Collaboration with Genome & Company

GENA-104 was initially discovered by Genome & Company, a forward-thinking biotechnology company based in South Korea. With a focused approach on developing novel cancer targets, Genome has paved the way for Ellipses to take charge of the future clinical development of GENA-104, designated under the identifier EP0089. This move signifies a strategic collaboration aimed at advancing cutting-edge cancer treatments.

Research Findings and Clinical Trials

The excitement surrounding EP0089 has been underpinned by recent studies published in a prestigious scientific journal that highlight its potential as a novel immuno-oncology treatment. These findings suggest that EP0089 could revolutionize how treatments are administered to patients, particularly those who have limited options. Following the approval of a Phase 1 IND by the South Korean Ministry of Food and Drug Safety, Ellipses aims to initiate clinical trials in South Korea, with plans to expand research to the US and Europe, contingent on securing regulatory approvals.

Executive Insights

Professor Sir Chris Evans, OBE, the Executive Chair of Ellipses, shared his enthusiasm regarding this promising drug candidate, highlighting its potential to change lives by speeding up the clinical trial process to bring effective treatments to patients. In agreement, Professor Tobias Arkenau, the Chief Medical Officer at Ellipses, emphasized the unique approach of targeting CNTN4, which he believes offers hope to patients suffering from various cancers that do not respond effectively to standard checkpoint inhibitors.

Affirmation from Genome's Leadership

Y.S. (Yoo Seok) Hong, CEO of Genome & Company, expressed confidence in the capabilities of Ellipses Pharma. He acknowledged the strong preclinical foundation of GENA-104 as a target immuno-oncology agent and is optimistic about the promising developments set to follow as clinical trials progress.

About Ellipses Pharma Limited

Ellipses Pharma Limited is strategically positioned to revolutionize cancer treatment globally. The company leverages a unique drug development model that incorporates comprehensive asset selection vetting, a robust Scientific Affairs Group comprising over 300 leading oncologists, and a steady funding pipeline to ensure quick progression through clinical trials. This model is integral in the rapid advancement of promising therapies like EP0089, ensuring they reach patients as soon as possible.

About Genome & Company

Genome & Company focuses on discovering and developing novel cancer target antibodies as well as antibody-drug conjugates. Utilizing their GNOCLE™ drug discovery platform, they integrate real-world clinical data to foster innovation within the oncology sector.

Frequently Asked Questions

What is GENA-104?

GENA-104 is a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, a protein involved in various tumors.

Who is developing GENA-104?

Ellipses Pharma Limited is responsible for the clinical development of GENA-104 after in-licensing it from Genome & Company.

What are the clinical trial plans for EP0089?

Ellipses Pharma aims to initiate Phase 1 clinical trials for EP0089 in South Korea and expand into the US and Europe pending regulatory approval.

How might EP0089 help cancer patients?

EP0089 offers a novel approach to target specific cancer proteins, potentially enhancing treatment responses for patients who do not benefit from existing therapies.

What is the focus of Ellipses Pharma?

Ellipses Pharma focuses on accelerating the development of cancer treatments through innovative strategies, prioritizing effective therapies for patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 99

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 133

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 161

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 34

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 75

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 51

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 177

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 183

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 93

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading

Top 5 Most Recently Viewed Articles

10 Strategies for Real Estate Investors: Stay Ahead of Risks

Updated Category Real Estate Views 1172

Introduction: 10 Easy Tips for Smart Property Investors Are you inve­sting in real estate? Pre­pare ahead to avoid costly surprises down the­ road. Imagine buying a property only to learn about hidde­n issues later. Wouldn't it be be­tter to anticipate risks early on? In re­al estate, staying informed can make­ or break your success. That's why this guide will help...

Continue Reading
Investors Show Strong Interest in Nike Options Trading Activity

Updated Category News Views 181

Market Whales and Their Recent Bets on NKE Options Recently, there has been significant interest among prominent investors in Nike, showcasing a bullish attitude toward the stock. Analyzing Options Trades for Nike (NYSE: NKE) Upon reviewing Nike's options history, we've identified multiple trades that reflect a notable trend. A clear majority of 50% of these trades have...

Continue Reading
AdTech Holding Celebrates Prestigious Workplace Certification

Updated Category News Views 176

AdTech Holding Achieves Recognition for Workplace Excellence AdTech Holding has recently earned the esteemed Great Place To Work® Certification™ for the third consecutive year. This notable achievement reflects the genuine feedback from employees concerning the workplace culture, trust, and the opportunities for professional growth that the company fosters. A...

Continue Reading
Innovative Truck Bed Design Revolutionizes Hauling for Drivers

Updated Category News Views 285

Enhancing Pickup Truck Hauling with Innovative Designs Many truck owners often face the challenge of maximizing their vehicle's hauling capabilities, especially when it comes to transporting large loads. One inventive solution that rises to this challenge is the BRIELLA TRUCK BEDS. This innovative design allows pickup trucks to convert effectively into flatbed trucks,...

Continue Reading
Investigation on Behalf of Long-Term Shareholders of Multiple Companies

Updated Category News Views 131

Investigation Into Geron Corporation and Other Companies Johnson Fistel, PLLP is conducting an investigation into potential violations of both federal and state securities laws. This inquiry focuses on the actions of certain officers and directors within Geron Corporation, Viatris Inc., Everus Construction Group, Inc., and SoundHound AI, Inc. Shareholders, particularly...

Continue Reading